Closing the Gender Health Gap: A One Trillion Dollar Opportunity

Women make up half the population, drive most healthcare decisions, and yet face worse outcomes in multiple conditions across their lifetimes. The cost of this gap is measured not only in years of life and quality of life lost, but also in lost productivity and avoidable healthcare spending. Closing the gender health gap is both a public health priority and one of the most significant emerging opportunities in healthcare investing.

What Do We Mean by the Gender Health Gap in Women's Health?

The gender health gap represents the measurable difference between women's potential health outcomes and their current reality across every stage of life. According to landmark research from the McKinsey Health Institute and the World Economic Forum, women spend 25 percent more of their lives in poor health compared to men, despite similar or even higher healthcare spending.

This gap shows up not just in reproductive health, but across:

• Chronic disease management
• Mental health
• Cardiovascular care
• Healthy longevity

For too long, women's health has been simplified to reproductive care alone. This narrow framing has created systematic blind spots in research, diagnosis, and treatment for conditions that affect women differently than men, from heart disease and autoimmune disorders to Alzheimer's disease and chronic pain.

When we examine the full scope of conditions where women face worse outcomes, inadequate research, or delayed diagnosis, we see that women's health is not a niche category. It is core economic infrastructure that has been chronically underbuilt.

The economic case is compelling. The World Economic Forum estimates that closing this gap could:

• Add the equivalent of seven healthy days per year for every woman globally
• Boost the world economy by at least one trillion dollars annually by 2040

These gains would come through reduced healthcare costs, increased workforce participation, and improved productivity. For investors, this represents a structural market opportunity comparable in scale and timing to early investments in fintech or climate technology.

How Big Is the One Trillion Dollar Women's Health Opportunity for Investors?

The numbers reveal a striking paradox at the heart of healthcare. Women make approximately 80 percent of household healthcare decisions, yet women's health has historically received roughly two percent of health-related venture funding. Women spend more years living with disability or chronic conditions than men, yet the medical research and product development infrastructure has consistently centered male biology as the default.

The economic value of closing this gap flows through three primary channels:

1. Fewer years lived with disability
   Research suggests potential gains of 75 million disability-adjusted life years annually worldwide if the women's health gap were closed.
2. Greater participation in paid work
   Nearly half of the healthy years women lose come during their prime working years, between ages 20 and 60. Addressing conditions like menopause alone—which costs the U.S. economy an estimated 26.6 billion dollars annually in lost productivity and medical expenses according to Mayo Clinic research—could unlock significant economic potential.
3. Lower downstream healthcare costs
   Prevention and earlier diagnosis reduce the need for expensive, late-stage care. Complicated pregnancies, delayed autoimmune diagnoses, and late-stage chronic disease treatment all generate substantially higher costs than proactive, sex-specific care.

For institutional investors, this opportunity resembles other structural market inefficiencies that created outsized returns for early movers. When fintech emerged, traditional financial services had systematically underserved large consumer segments. When climate technology accelerated, energy markets had failed to price environmental externalities. Women's health today presents a similar pattern: massive unmet need, structural underinvestment, and growing recognition that the status quo is economically unsustainable.

Why Has Women's Health Received Only Two Percent of Health Venture Funding?

The historical underinvestment in women's health stems from interconnected biases in research, clinical practice, and capital allocation. Understanding these root causes helps investors recognize where structural change is creating new market opportunities.

Historical Bias in Research and Development

Until 1993, federally funded clinical research in the United States was not required to include women and minorities. The consequences of this exclusion persist today.

A U.S. Government Accountability Office audit found that eight of ten drugs withdrawn from the U.S. market between 1997 and 2001 posed greater health risks for women than men, largely because these drugs were not sufficiently tested on women. Recent systematic reviews continue to document underrepresentation of women in clinical trials across therapeutic areas including cardiovascular disease, diabetes, and oncology.

Beyond trial participation, narrow definitions of women's health have historically concentrated research funding on fertility and pregnancy while neglecting how conditions like heart disease—which kills more women than all cancers combined—manifest differently in women. The result is a medical evidence base that often treats women as smaller men rather than as biologically distinct patients requiring tailored approaches.

Investor Misconceptions

Several persistent misconceptions have limited venture capital investment in women's health:

• Markets are perceived as small or fragmented, when in reality conditions affecting 50 percent of the population represent massive total addressable markets.
• Women's health is often assumed to be primarily a consumer category with limited payer interest, despite growing evidence that employers, health plans, and health systems are increasingly willing to fund solutions that reduce long-term costs and improve outcomes.
• The perception that women's health lacks “blockbuster” potential ignores both the scale of unmet need and the commercial success of solutions that do reach market—fertility treatments being a clear example.

Structural Issues in Venture Capital

The venture capital industry itself reflects patterns that limit investment in women's health. According to PitchBook data, women hold approximately 17 percent of decision-making roles at venture capital firms with more than 50 million dollars in assets under management.

Research consistently shows that venture firms with female partners are significantly more likely to invest in companies addressing women's health needs. The underrepresentation of women in check-writing positions creates a pattern recognition problem: investors may simply be less likely to recognize the scale of opportunity in markets they do not personally experience.

Where Does the Gender Health Gap Show Up Across Conditions and Life Stages?

Portfolia approaches women's health through a three-lens framework that captures the full scope of investment opportunity:

• Conditions specific to women
• Conditions that affect women differently
• Conditions that affect women disproportionately

Conditions Specific to Women

Reproductive health conditions remain obvious but persistently underserved markets.

• Endometriosis affects an estimated 10 percent of reproductive-age women globally, yet diagnosis takes an average of seven years and involves consulting multiple clinicians. The annual economic burden of endometriosis in the United States is estimated between 78 and 119 billion dollars when accounting for direct medical costs and productivity losses. Treatment options remain limited, with only about 20 drugs currently in global development for the condition.
• Menopause and perimenopause affect more than one billion women worldwide at any given time. Research from the Mayo Clinic found that menopause symptoms cost the U.S. economy 1.8 billion dollars annually in lost work time alone, with an additional 24.8 billion dollars in direct medical costs. Despite these figures, studies show that only one-fifth of obstetrician-gynecologists report formal training related to menopause, and a global analysis found that 58 percent of medical textbooks contain no mention of menopause.
• Maternal health presents both urgent clinical need and commercial opportunity. The United States has the highest maternal mortality rate among developed nations, with rates nearly doubling over the past two decades. Conditions like preeclampsia, which affects one in 12 U.S. pregnancies, currently lack predictive tools that can identify risk early enough for effective intervention. The annual healthcare costs of preeclampsia alone exceed two billion dollars in the first 12 months after diagnosis.

Read Also: The $180 Billion Endometriosis Opportunity - Why Investors Are Still Early to This Women's Health Market

Conditions That Affect Women Differently

Some conditions affect both men and women but present differently, respond differently to treatment, or carry higher risk for women.

• Cardiovascular disease is the leading cause of death for women, yet women are significantly underrepresented in cardiovascular clinical trials. An analysis of trials registered between 2010 and 2017 found that women comprised less than 40 percent of participants. Women are more likely to present with atypical symptoms that can delay diagnosis and treatment, and more likely to have microvascular disease in the small arteries of the heart, which is harder to detect with standard diagnostic tools. When women do present with cardiac symptoms, they are more likely than men to experience delays in receiving care and less likely to receive certain treatments.
• Autoimmune diseases disproportionately affect women, with approximately 80 percent of all autoimmune disease patients being female according to NIH data. Conditions like lupus affect women at a seven-to-one ratio compared to men, while Sjögren's syndrome affects women at a nine-to-one ratio. Autoimmune diseases are the fifth leading cause of death in women younger than 65, and women with these conditions face 50 percent higher risk of dying from cardiovascular disease compared to men with the same conditions.
• Alzheimer's disease affects women at nearly twice the rate of men. Of the 7.2 million Americans age 65 and older living with Alzheimer's, 4.4 million are women. While longevity explains part of this disparity, researchers are increasingly examining whether sex-specific biological factors, including hormonal changes at menopause, create distinct risk profiles that require different prevention and treatment approaches.

Conditions That Affect Women Disproportionately

Some conditions affect all genders but fall more heavily on women.

• Osteoporosis affects approximately ten million Americans, with 80 percent being women. A woman's risk of breaking a hip equals her combined risk of breast, uterine, and ovarian cancer. Half of all women over age 50 will break a bone due to osteoporosis. The disease often goes undiagnosed until a fracture occurs, creating opportunities for earlier screening and intervention.
• Mental health conditions including anxiety and depression affect women at roughly twice the rate of men. These disparities intersect with other health conditions: women with autoimmune diseases face 47.6 percent higher risk of mood disorders compared to men with the same conditions. The economic burden extends beyond healthcare costs to include impacts on work, caregiving capacity, and quality of life.

What Does the One Trillion Dollar Estimate Mean in Practical Terms for Investors?

The McKinsey and World Economic Forum analysis translates the gender health gap into economic terms that highlight specific investment opportunities.

The largest impact; approximately 400 billion dollars of the total opportunity—would come through fewer health conditions overall. Treatment of just ten conditions, including premenstrual syndrome, depressive symptoms, and migraines, could generate more than half of the projected economic gains.

Beyond reduced disease burden, closing the gender health gap would enable expanded workforce participation. Addressing menopause alone could have impact equivalent to the economic contributions of millions of additional women in full-time positions. Increased productivity from healthier workers and reduced unpaid caregiving burden would contribute additional economic value.

For investors, these gains translate into several investable themes:

• Earlier diagnosis through data and diagnostics that identify risk before costly complications develop
• Condition-specific digital care models that improve outcomes while reducing per-patient costs
• New therapeutics and devices tailored to women's biology in underserved markets
• Infrastructure and enablement tools that make the health system work better for women, from care navigation to provider training

Institutional investors increasingly view women's health as a distinct asset theme rather than a subsector of broader healthcare. The combination of demographic tailwinds, regulatory attention, employer demand, and shifting payer willingness to fund prevention creates conditions for category-defining companies to emerge.

Where Is Innovation Already Closing the Gender Health Gap in Women's Health?

How Are Portfolio Companies Rethinking Reproductive and Fertility Health?

Innovation in reproductive health is making care more accessible, effective, and personalized. Companies are developing approaches that:

• Reduce the time, cost, and burden of fertility treatment while improving success rates
• Expand contraceptive options beyond hormonal methods that do not work for all women
• Bring predictive capabilities to pregnancy care, identifying risk earlier when intervention can make the greatest difference

These innovations share common characteristics. They leverage data and technology to personalize care, reduce friction in the patient experience, and demonstrate clear value to payers by reducing downstream costs. Most importantly, they address needs that women have articulated for decades but that the traditional healthcare system has failed to prioritize.

How Are Innovators Tackling Chronic Conditions That Affect Women Differently?

Cardiovascular health innovation is beginning to recognize sex-specific differences in disease presentation and treatment response. New diagnostic approaches can identify microvascular disease patterns more common in women. Risk assessment tools are incorporating sex-specific factors that traditional algorithms overlooked. Treatment protocols are being tailored to account for differences in drug metabolism and side-effect profiles.

Autoimmune disease management is evolving to recognize the hormonal influences that contribute to the female predominance of these conditions. Companies are developing diagnostics that can identify autoimmune disease earlier, reducing the years of suffering and misdiagnosis that patients currently experience. Care platforms are integrating the multiple specialists these patients often require.

How Are New Models Supporting Healthy Longevity for Women?

Menopause care has emerged as one of the fastest-growing segments of women's health innovation. Virtual clinics are making evidence-based menopause treatment accessible to women who previously had limited options. Precision approaches are matching women with the therapies most likely to address their specific symptom profiles. Consumer-grade experiences are normalizing a life stage that affects billions of women.

Bone health innovation is addressing the post-menopausal osteoporosis risk that affects the majority of older women. Brain health companies are examining whether sex-specific approaches to cognitive decline prevention could reduce women's disproportionate Alzheimer's burden. These longevity markets represent a critical piece of the one trillion dollar upside, as the population of midlife and older women grows globally.

What Have We Learned About Winning Companies in the Gender Health Gap?

Across Portfolia's women's health investments, patterns emerge that distinguish companies positioned for lasting impact from those that address surface-level opportunities.

Winning companies tend to share these traits:

• Science-based and data-informed products rather than marketing-led solutions. The most successful companies generate proprietary data that improves their products over time, creating competitive moats that are difficult to replicate.
• Clear, measurable outcomes for women and the health system. Companies that can show improved clinical outcomes alongside reduced costs attract interest from employers, health plans, and health systems. Those that rely solely on consumer willingness to pay face more constrained market opportunities.
• Aligned business models that benefit patients, payers, and employers. When all stakeholders gain from improved outcomes, companies can build durable market positions. Misaligned incentives, by contrast, create friction that limits growth.
• Deep integration of women's lived experience in product design. Companies that design around how women actually experience their health journeys—rather than how the medical system categorizes their conditions—build stronger patient loyalty and better outcomes. Diversity in leadership, clinical trials, and advisory boards correlates with products that truly serve diverse patient populations.

The evidence increasingly shows that women's health is not a single point-solution category but a set of scalable platforms across conditions and life stages. Companies that can address multiple needs for the same patient base often build more defensible businesses than those addressing isolated symptoms.

How Should Investors Evaluate Women's Health Companies That Claim to Close the Gender Health Gap?

Not every company labeled as women's health addresses the core inefficiencies that create investment opportunity. Rigorous evaluation requires examining several dimensions:

• Does the company address a material contributor to the gender health gap?
  The most attractive opportunities tackle conditions where women face meaningfully worse outcomes, inadequate research, or delayed diagnosis compared to men.
• Is there credible evidence of demand and willingness to pay?
  Signals from patients, employers, health plans, and health systems all matter. Consumer demand alone may not translate into sustainable business models if payer economics do not support the solution.
• Does the model scale?
  Regulatory pathway, reimbursement strategy, unit economics, and path to profitability all require scrutiny. Some approaches may genuinely help individual patients but prove difficult to deploy at scale.
• Is women's experience embedded in the company?
  Representation in leadership, product development, clinical strategy, and go-to-market execution all influence whether a company can authentically serve women's health needs.

Companies built by people who deeply understand the patient experience they seek to improve often make better product decisions than those approaching women's health purely as a market opportunity.

What Makes Portfolia a Purpose-Built Platform for Investing in the Gender Health Gap?

Portfolia pioneered women's health investing when few institutional investors recognized the category. Today, Portfolia stands as the most active venture fund capital in women's health globally, with more than 46 portfolio companies and over 100 investments across multiple funds dedicated to the sector.

This track record includes early investments in category-defining companies that have achieved significant valuations and clinical milestones. The depth of portfolio exposure provides both pattern recognition for evaluating new opportunities and platform effects that benefit portfolio companies through shared learnings and connections.

Portfolia's community-based investing model distinguishes it from traditional venture capital. A network of more than 2,000 investors brings both capital and lived experience to the investment process. This community helps:

• Identify unmet needs that institutional investors might miss
• Provide real-world feedback on portfolio company products
• Create networks that accelerate company development

The Portfolia approach complements traditional venture capital and institutional capital by providing patient capital focused specifically on women's health, deep sector expertise, and an engaged investor community. For companies, Portfolia offers not just funding but access to a network that understands the problems they are solving.

How Can Investors Join Portfolia in Closing the Gender Health Gap?

The one trillion dollar opportunity in women's health is both timely and underserved. Demographic trends, regulatory attention, and shifting payer priorities are creating tailwinds for innovation. Yet despite record venture investment in women's health reaching 2.6 billion dollars in 2024 according to Silicon Valley Bank data, the sector remains dramatically underfunded relative to its economic potential and health burden.

Accredited investors, qualified purchasers, and family offices play a critical role in moving capital into women's health at the scale needed to close the gender health gap. Early-stage companies addressing conditions like menopause, maternal health, and autoimmune disease need patient capital from investors who understand the unique dynamics of women's health markets.

Portfolia offers multiple ways to engage:

• The Women's Health Fund provides diversified exposure to a curated portfolio of companies addressing the gender health gap.
• Educational programming, diligence sessions, and portfolio company interactions allow investors to deepen their understanding of the space.
• The Portfolia community connects investors with founders, fellow investors, and healthcare leaders working to transform women's health.

The gender health gap represents one of healthcare's most significant market inefficiencies. For investors seeking both financial returns and meaningful impact, women's health offers a rare alignment of opportunity and purpose. Investors can review fund materials and speak with Portfolia’s team to understand how women's health fits into their broader investment strategy.

‍